All News
Filter News
Found 45 articles
-
Money on the Move: July 21 – 27, 2021
7/28/2021
A quick overview of life science companies scooping up some summer spending money this week. -
The Cambridge-based company is targeting the DNA Damage Response (DDR) pathway to attack various cancers.
-
Artios Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X
7/27/2021
Artios Pharma Limited, a leading DNA Damage Response company exploiting a broad DDR-based platform and small molecule drug discovery capabilities to develop a diverse pipeline of product candidates for the treatment of cancer, announced the completion of a US$153 million Series C financing to fund further development of its promising clinical-stage pipeline.
-
Artios Pharma Publishes Preclinical Data on The First Selective Small Molecule Polθ Polymerase Inhibitor in Nature Communications
6/17/2021
Artios Pharma Limited announced the publication of a peer reviewed article titled, “Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance” in Nature Communications.
-
CatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer
5/4/2021
CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, announced the appointment of Dr. Phil L’Huillier as Chief Executive Officer, effective May 17, 2021.
-
Artios Pharma Limited has entered into a global research collaboration with Novartis for the purpose of discovering and validating next-generation DDR targets and enhancing Novartis’ radioligand therapies.
-
Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies
4/7/2021
Artios eligible to receive up to $1.3 billion in discovery, development, regulatory and sales-based milestones in addition to royalty payments.
-
Amathus Therapeutics, a biopharmaceutical company working on small molecule modulators across diverse genetically defined diseases, has entered into a strategic collaboration with Merck to develop novel small molecule treatment candidates for neurodegenerative diseases.
-
DNA Repair Drugs Market: Rise in prevalence of cancer among population is likely to fuel the growth of the market
1/14/2021
DNA damage is an abnormal structure in DNA that leads to change in structure of genetic material and prevents the replication mechanism from functioning and performing properly.
-
Merck KGaA and Artios Pharma Limited announced today that they have entered a strategic collaboration agreement to discover and develop multiple precision oncology drugs over the course of the next three years.
-
Artios and Merck KGaA announce global strategic collaboration
12/3/2020
Arix Bioscience plc (“Arix”, LSE: ARIX) a global venture capital company focused on investing in and building breakthrough biotech companies, notes that portfolio company Artios Pharma Limited (“Artios”), a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, and Merck KGaA, Darmstadt, Germany (“Merck KGaA”)
-
BioSpace Movers & Shakers, June 12
6/12/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Amolyt Pharma Appoints Pierre Legault as a Director and Chairman of its Board of Directors as Company Transitions into Clinical Stage
6/9/2020
Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, announced the appointment of Pierre Legault, MBA, CPA as director and chairman of its board of directors.
-
Under the new deal, Artios Pharma licensed rights to research, develop, manufacture and commercialize products globally from a small-molecule ATR inhibitor program that was jointly developed by MD Anderson and ShangPharma.
-
Artios Pharma, MD Anderson and ShangPharma announce in-licensing agreement for DNA damage response inhibitor
11/6/2019
Artios Pharma Limited, The University of Texas MD Anderson Cancer Center and ShangPharma Innovation announce the in-licensing by Artios of a small-molecule ATR inhibitor programme, developed jointly by MD Anderson and ShangPharma.
-
Artios Pharma appoints Tania Dimitrova as Chief Business Officer and expands presence in the United States
9/24/2019
Artios Pharma Limited announces the appointment of Tania Dimitrova as Chief Business Officer and its expanded presence in the United States.
-
Artios Pharma Announces Appointment of Dr. Ian Smith as Chief Medical Officer
4/1/2019
Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of innovative treatments for cancer, today announces the appointment of Ian Smith, M.D., as Chief Medical Officer
-
Artios Pharma Announces Appointment of Professor Rajesh Chopra as Non-Executive Director
2/11/2019
Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of innovative treatments for cancer, today announced the appointment of Professor Rajesh Chopra as Non-Executive Director (NED).
-
Artios Pharma Wins 2018 Lifestars EU Private Finance Raise of the Year Award
11/14/2018
Artios Pharma Limited is pleased to announce that it has won the 2018 Lifestars “>£30m EU Private Finance Raise of the Year” Award.
-
Arix Bioscience plc Co-leads $58 million Series A investment round for VelosBio
10/1/2018
Arix co-leads a $58 million Series A investment in new Group Business, VelosBio Inc., bringing core portfolio1 to 15 companies